Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma

Pancreas

Volumn 29, Issue 3, 2004, Pages 204-211

  Niedergethmann, Marco ^a   Wostbrock, Birgit ^a   Sturm, Jörg W ^a   Willeke, Frank ^a   Post, Stefan ^a   Hildenbrand, Ralf ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cathepsin B; Cathepsin L; Curative surgery; In situ hybridization; Pancreatic adenocarcinoma; Prognosis

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYSTEINE PROTEINASE; MESSENGER RNA; POLYCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CELL TYPE; CELLULAR DISTRIBUTION; CORRELATION ANALYSIS; CYTOPLASM; DISEASE COURSE; ENZYME SYNTHESIS; FEMALE; FIBROBLAST; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR VOLUME;

ADULT; AGED; CARCINOMA, PANCREATIC DUCTAL; CATHEPSIN B; CATHEPSINS; COMBINED MODALITY THERAPY; CYSTEINE ENDOPEPTIDASES; ENDOTHELIAL CELLS; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION; ISLETS OF LANGERHANS; LIFE TABLES; LIVER NEOPLASMS; MACROPHAGES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; SUBCELLULAR FRACTIONS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 4644236863     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006676-200410000-00005     Document Type: Article

References (40)

1. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma: clinico-pathologic analysis of 5-year survivors. Ann Surg. 1996;223:273-279.
2. Yamaue H, Tani M, Onishi H, et al. Locoregional Chemotherapy for patients with pancreatic cancer: intra-arterial adjuvant chemotherapy after pancreatectomy with portal vein resection. Pancreas. 2002;25:366-372.
3. Richter A, Niedergethmann M, Hartel M, et al. Longterm results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head - a 25-year experience. World J Surg. 2003;27:324-329.
4. Boehle AS, Kalthoff H. Molecular mechanisms of tumor metastasis and angiogenesis. Langenbecks Arch Surg. 1999;384:133-140.
5. Ellenrieder V, Adler G, Gress TM. Invasion and metastasis in pancreatic cancer. Ann Oncol. 1999;10:46-50.
6. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic cancer. Br J Cancer. 1997;75:388-395.
7. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastases. Clin Exp Met. 1992;10:145-155.
8. Sloane BF, Dunn JR, Honn KV. Lysosomal Cathepsin B: correlation with metastatic potential. Science. 1981;212:1151-1153.
9. Szpaderska AM, Frankfater A. An intracellular form of cathepsin B contributes to invasiveness in cancer. Cancer Res. 2001;61:3493-3500.
10. Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol. 1990;1:137-152.
11. Im B, Kominami E, Grube D, et al. Immunohistocytochemical localization of cathepsin B and H in human pancreatic endocrine cells and insulinoma cells. Histochemistry. 1998;93:111-118.
12. Kuliawat R, Klumperman J, Ludwig T, et al. Differential sorting of lysosomal enzymes out of the regulated secretory pathway in pancreatic β-cells. J Cell Biol. 1997;137:595-608.
13. Chauhan SS, Goldstein LJ, Gottesmann MM. Expression of cathepsin L in human tumors. Cancer Res. 1991;51:1478-1481.
14. Kobayashi H, Schmitt M, Goretzki L, et al. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem. 1991;266:5147-5152.
15. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood. 1987;69: 381-387.
16. Ohta T, Terada T, Nagakawa T. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesion. Br J Cancer. 1994;69:152-156.
17. Tumminello FM, Leto G, Pizzolanti G, et al. Cathepsin D, B and L circulating levels as prognostic markers of malignant progression. Anticancer Res. 1996;16:2315-2320.
18. Breslow NE. Analysis of survival data under the proportional hazards model. Int Stat Rev. 1975;43:45-58.
19. Gal S, Gottesmann MM. Isolation and sequence of a cDNA for human pro-(cathepsin L). Biochem J. 1988;253:303-306.
20. Tam SW, Cote-Paulino LR, Peak DA, et al. Human cathepsin B encoding cDNAs: sequence variations in the 3′-untranslated region. Gene. 1994; 139:171-176.
21. Braissant O, Wahli W. A simplified in situ hybridization protocol using non-radioactive labeled probes to detect abundant and rare mRNAs on tissue sections. Biochemica. 1998;1:10-16.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-458.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
24. Takai S, Sato S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003;26:243-249.
25. Sloane BF, Rozhin J, Johnson K, et al. Cathepsin B: association with plasma membrane in metastatic tumors. Proc Natl Acad Sci USA. 1986; 83:2483-2487.
26. Thomssen C, Schmitt M, Goretzki L, et al. prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res. 1995;1:741-746.
27. Sheahan K, Shuja S, Murnane MJ. Cysteine protease activities and tumor development in human colorectal carcinoma. Cancer Res. 1989;49:3809-3814.
28. Paciucci R, Tora M, Diaz V, et al. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene. 1998;16:625-633.
29. Wang W, Abbruzzese JL, Evans DB, et al. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene. 1999;18:4554-4563.
30. Hildenbrand R, Dilger I, Horlin A, et al. Urokinase and macrophages in tumour angiogenesis. Br J Cancer. 1995;72:818-823.
31. Sanchez-Martin MM, Cabezas JA, Ortega S, et al. Levels of serum cathepsin L and several glycosidases in patients operated for colorectal cancer. Cancer Lett. 1999;I41:73-77.
32. Fernandez PL, Farre X, Nadal A, et al. Expression of cathepsins B and S in the progression of prostate carcinoma. Int J Cancer. 2001;95:51-55.
33. Lah TT, Kokalj-Kunovar M, Strukelj B, et al. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int J Cancer. 1992;50: 36-44.
34. Niedergethmann M, Hildenbrand R, Wolf G, et al. Angiogenesis and cathepsin expression are prognostic factors in pancreatic cancer after curative resection. Int J Pancreatol. 2000;28:33-41.
35. Leto G, Tumminello FM, Pizzolanti G, et al. Lysosomal aspartic and cysteine proteinases serum levels in patients with pancreatic cancer or pancreatitis. Pancreas. 1997;14:22-27.
36. Yamaguchi N, Chung SM, Shiroeda O, et al. Characterization of a cathepsin L-like enzyme secreted from human pancreatic cancer cell line HPC-YP. Cancer Res. 1990;50:658-663.
37. Hartel M, Niedergethmann M, Farag-Soliman M, et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg. 2002;168:707-712.
38. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control. 2000;7:421-427.
39. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79:1553-1563.
40. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of VEGF in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-1316.